Weekly Analysts’ Ratings Updates for Assertio (ASRT)

A number of firms have modified their ratings and price targets on shares of Assertio (NASDAQ: ASRT) recently:

• 4/20/2026 – Assertio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/9/2026 – Assertio was downgraded by Maxim Group from “strong-buy” to “hold”.
• 4/9/2026 – Assertio was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $18.00 price target on the stock, down from $45.00.
• 4/9/2026 – Assertio had its “neutral” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock, down from $35.00.
• 3/21/2026 – Assertio was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/6/2026 – Assertio was downgraded by Zacks Research from “strong-buy” to “hold”.

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.